The demand is driven by the expansion of the market to $100 million per year through the popularization of other peptide-based drugs, such as Ozempic and Wegovy. These include biohacking drugs — from appetite suppression to damaged cell regeneration. The shift to cryptocurrencies is prompted by the increasing share of Chinese manufacturers who are cut off from the banking sector. Among major suppliers, stablecoin payments are prevalent. This is necessary to protect large orders from token price fluctuations. Chainalysis also notes that some organizations associated with the sale of fentanyl and other narcotics are transitioning to peptides. For example, Shanghai Sigma Audley received $4.6 million in cryptocurrency from drug sales before moving to peptides.